> Details

Schwertner, Barbara; Lindner, Georg; Toledo Stauner, Camila Toledo; Klapproth, Elisa; Magnus, Clara; Rohrhofer, Anette; Gross, Stefanie; Schuler-Thurner, Beatrice; Öttl, Veronika; Feichtgruber, Nicole; Drexler, Konstantin; Evert, Katja; Krahn, Michael P.; Berneburg, Mark; Schmidt, Barbara; Schuster, Philipp; Haferkamp, Sebastian

Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo
  • Contributor: Schwertner, Barbara; Lindner, Georg; Toledo Stauner, Camila Toledo; Klapproth, Elisa; Magnus, Clara; Rohrhofer, Anette; Gross, Stefanie; Schuler-Thurner, Beatrice; Öttl, Veronika; Feichtgruber, Nicole; Drexler, Konstantin; Evert, Katja; Krahn, Michael P.; Berneburg, Mark; Schmidt, Barbara; Schuster, Philipp; Haferkamp, Sebastian
  • Published: MDPI AG, 2021
  • Published in: Cancers, 13 (2021) 12, Seite 3058
  • Language: English
  • DOI: 10.3390/cancers13123058
  • ISSN: 2072-6694
  • Origination:
  • Footnote:
  • Description: Talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus, is approved for intralesional injection of unresectable stage IIIB/IVM1a melanoma. However, it is still unclear which parameter(s) predict treatment response or failure. Our study aimed at characterizing surface receptors Nectin-1 and the herpes virus entry mediator (HVEM) in addition to intracellular molecules cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) as potential bio-markers for oncolytic virus treatment. In 20 melanoma cell lines, oncolytic activity of T-VEC was correlated with the expression of Nectin-1 but not HVEM, as evaluated via flow cytometry and immunohistochemistry. Knockout using CRISPR/Cas9 technology confirmed the superior role of Nectin-1 over HVEM for entry and oncolytic activity of T-VEC. Neither cGAS nor STING as evaluated by Western Blot and immunohistochemistry correlated with T-VEC induced oncolysis. The role of these biomarkers was retrospectively analyzed for the response of 35 cutaneous melanoma metastases of 21 patients to intralesional T-VEC injection, with 21 (60.0%) of these lesions responding with complete (n = 16) or partial regression (n = 5). Nectin-1 expression in pretreatment biopsies significantly predicted treatment outcome, while the expression of HVEM, cGAS, and STING was not prognostic. Altogether, Nectin-1 served as biomarker for T-VEC-induced melanoma regression in vitro and in vivo.
  • Access State: Open Access